Molecular mechanisms of [18F]fluorodeoxyglucose accumulation in liver cancer

Oncol Rep. 2014 Feb;31(2):701-6. doi: 10.3892/or.2013.2886. Epub 2013 Nov 29.

Abstract

To elucidate the molecular mechanisms underlying the insufficient sensitivity in the detection of hepatocellular carcinoma (HCC) by [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), the characteristics of glucose metabolism-related protein expression in HCC were examined in liver metastasis from colorectal cancer (Meta). Thirty-four patients (14 Meta and 20 HCC) who underwent FDG-PET and hepatectomy were studied. The relationships between the maximum standardized uptake value (SUV) in tumors and the mRNA expression of glucose metabolism-related proteins [hexokinase (HK), glucose transporter 1 (GLUT1), and glucose-6-phosphatase (G6Pase)] and proliferating cell nuclear antigen (PCNA) were examined in snap-frozen specimens with quantitative PCR. Tumor detection rates were lower in HCC (15/20) compared to Meta (13/14) patients. HK and GLUT1 expression was lower and G6Pase expression was higher in HCC compared to Meta. In particular, GLUT1 overexpression was 92-fold in Meta and 11-fold in HCC compared to the surrounding liver. The SUV correlated with GLUT1 and PCNA expression in HCC, but not Meta patients. Of note, four cases of poorly differentiated (P/D) HCC compared to moderately differentiated (M/D) HCC produced completely different results for FDG uptake (SUV, 14.4 vs. 4.0) and mRNA expression (G6Pase expression, 0.007 vs. 1.5). Variations in the expression of glucose metabolism-related enzymes between HCC and Meta patients are attributed to origin or degree of differentiation. Low FDG uptake in M/D HCC reflected low GLUT1 and high G6Pase expression, while high FDG accumulation in P/D HCC could reflect increased GLUT1 and decreased G6Pase expression. These results may explain why M/D HCC is not detected as sensitively by FDG-PET.

MeSH terms

  • Aged
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / diagnostic imaging*
  • Carcinoma, Hepatocellular / surgery
  • Female
  • Fluorodeoxyglucose F18* / chemistry
  • Glucose / metabolism*
  • Glucose Transporter Type 1 / analysis
  • Glucose Transporter Type 1 / genetics
  • Glucose Transporter Type 2 / analysis
  • Glucose-6-Phosphatase / genetics
  • Glucose-6-Phosphatase / metabolism
  • Glucose-6-Phosphate / analogs & derivatives
  • Glucose-6-Phosphate / chemistry
  • Hepatectomy
  • Hexokinase / analysis
  • Hexokinase / genetics
  • Humans
  • Liver / diagnostic imaging
  • Liver / metabolism
  • Liver / pathology
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / diagnostic imaging*
  • Liver Neoplasms / surgery
  • Male
  • Positron-Emission Tomography / methods*
  • Proliferating Cell Nuclear Antigen / genetics
  • RNA, Messenger / biosynthesis
  • Radiopharmaceuticals

Substances

  • Glucose Transporter Type 1
  • Glucose Transporter Type 2
  • Proliferating Cell Nuclear Antigen
  • RNA, Messenger
  • Radiopharmaceuticals
  • SLC2A1 protein, human
  • SLC2A2 protein, human
  • Fluorodeoxyglucose F18
  • 2-fluoro-2-deoxyglucose-6-phosphate
  • Glucose-6-Phosphate
  • Hexokinase
  • Glucose-6-Phosphatase
  • Glucose